Investors confirm $350 mln for Canada domiciled Aralez Pharma
POZEN Inc (NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc (TSX-V: TRX) have amended merger plans to create a new parent company, Aralez Pharmaceuticals Inc. The changes to the previously-announced deal include moving the domicle for Aralez from Ireland to Canada. In connection with the transaction, an investment syndicate has confirmed its commitment of up to US$350 million in growth capital for the combined entity. The financing will be led by U.S. healthcare investment firm Deerfield Management with participation from QLT Inc, Broadfin Capital and JW Asset Management. The POZEN-Tribute merger is expected to close in the first quarter of 2016.
8 December 2015•10 mins read
